The predictive value and evolution of N-terminal Pro-B-type natriuretic peptide levels following transcutaneous aortic valve implantation

Journal of Interventional Cardiology

Volumn 24, Issue 5, 2011, Pages 462-469

  Spargias, Konstantinos ^a   Polymeros, Spyros ^b   Dimopoulos, Antonis ^b   Manginas, Athanassios ^b   Pavlides, Gregory ^b   Balanika, Marina ^b   Smirli, Anna ^b   Stavridis, George ^b   Dangas, George ^c   Cokkinos, Dennis V ^d  

^a HYGEIA HOSPITAL   (Greece)

^b ONASSIS CARDIAC SURGERY CENTER   (Greece)

^c MOUNT SINAI MEDICAL CENTER   (United States)

^d BIOMEDICAL RESEARCH FOUNDATION   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE;

AGED; AORTA STENOSIS; ARTICLE; EVOLUTION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; TRANSCATHETER AORTIC VALVE IMPLANTATION;

AGED, 80 AND OVER; AORTIC VALVE; CHI-SQUARE DISTRIBUTION; ECHOCARDIOGRAPHY; FEMALE; HEALTH STATUS INDICATORS; HEART VALVE DISEASES; HEART VALVE PROSTHESIS IMPLANTATION; HUMANS; MALE; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; TIME FACTORS;

EID: 80054990148     PISSN: 08964327     EISSN: 15408183     Source Type: Journal    
DOI: 10.1111/j.1540-8183.2011.00654.x     Document Type: Article

References (22)

1. Svensson LG, Dewey T, Kapadia S, et al,. United States feasibility study of transcatheter insertion of a stented aortic valve by the left ventricular apex. Ann Thorac Surg 2008; 86: 46-55.
2. Walther T, Falk V, Kempfert J, et al,. Transapical minimally invasive aortic valve implantation; the initial 50 patients. Eur J Cardiothorac Surg 2008; 33: 983-938.
3. Grube E, Schuler G, Buellesfeld L, et al,. Percutaneous aortic valve replacement for severe aortic stenosis in high-risk patients using the second- and current third-generation self-expanding CoreValve prosthesis: Device success and 30-day clinical outcome. J Am Coll Cardiol 2007; 50: 69-76.
4. Webb JG, Pasupati S, Humphries K, et al,. Percutaneous transarterial aortic valve replacement in selected high-risk patients with aortic stenosis. Circulation 2007; 116: 755-763.
5. Walther T, Simon P, Dewey T, et al,. Transapical minimally invasive aortic valve implantation: Multicenter experience. Circulation 2007; 116: I240-I245.
6. Piazza N, Grube E, Gerckens U, et al,. Procedural and 30-day outcomes following transcatheter aortic valve implantation using the third generation (18 Fr) CoreValve ReValving system: Results from multicentre, expanded evaluation registry 1-year following CE mark approval. EuroInterv 2008; 4: 242-249.
7. Thomas M, Schymik G, Walther T, et al,. Thirty-day results of the SAPIEN aortic bioprosthesis European outcome (SOURCE) registry. A European registry of transcatheter aortic valve implantation using the Edwards SAPIEN valve. Circulation 2010; 122: 62-69.
8. Wendler O, Schymik G, Walther T, et al,. SOURCE REGISTRY TAVI: Development of a risk score for transcatheter aortic valve implantation: 1-year outcomes from over 1,000 patients in the source registry. Paper presented at: Annual Congress of the European Society of Cardiology, Stockholm, Sweden, August 29, 2010.
9. Weber M, Arnold R, Rau M, et al,. Relation of N-terminal pro B-type natriuretic peptide to progression of aortic valve disease. Eur Heart J 2005; 26: 1023-1030.
10. Gerber IL, Stewart RAH, Legget ME, et al,. Increased plasma natriuretic peptide levels reflect symptom onset in aortic stenosis. Circulation 2003; 107: 1884-1890.
11. Bergler-Klein J, Klaar U, Heger M, et al,. Natriuretic peptides predict symptom-free survival and postoperative outcome in severe aortic stenosis. Circulation 2004; 109: 2302-2308.
12. Neverdal NO, Knudsen CW, Husebye T, et al,. The effect of aortic valve replacement on plasma B-type natriuretic peptide in patients with severe aortic stenosis-one year follow-up. Eur J Heart Fail 2006; 8: 257-262.
13. Georges A, Forestier F, Valli N, et al,. Changes in type B natriuretic peptide (BNP) concentrations during cardiac valve replacement. Eur J Cardiothorac Surg 2004; 25: 941-945.
14. Ikeda T, Matsuba K, Itoh H, et al,. Plasma levels of brain and atrial natriuretic peptides elevate in proportion to left ventricular end-systolic wall stress in patients with aortic stenosis. Am Heart J 1997; 133: 307-314.
15. Talwar S, Downie PF, Squire IB, et al,. Plasma N-terminal pro BNP and cardiotrophin-1 are elevated in aortic stenosis. Eur J Heart Fail 2001; 3: 15-19.
16. Qi W, Mathisen P, Kjekshus J, et al,. Natriuretic peptides in patients with aortic stenosis. Am Heart J 2001; 142: 725-732.
17. Sagnella GA,. Measurement and significance of circulating natriuretic peptides in cardiovascular disease. Clin Sci 1998; 95: 519-529.
18. Hall C,. Essential biochemistry and physiology of (NT-pro)BNP. Eur J Heart Fail 2004; 6: 257-260.
19. Struthers AD,. Introducing a new role for BNP: As a general indicator of cardiac structural disease rather than a specific indicator of systolic dysfunction only. Heart 2022; 87:97- 98.
20. Kupari M, Turto H, Lommi J, et al,. Transcardiac gradients of N-terminal B-type natriuretic peptide in aortic valve stenosis. Eur J Heart Fail 2005; 7: 809-814.
21. Bergler-Klein J, Mundigler G, Pibarot P, et al,. B-type natriuretic peptide in low-flow, low-gradient aortic stenosis relationship to hemodynamics and clinical outcome: Results from the multicenter truly or pseudo-severe aortic stenosis (TOPAS) study. Circulation 2007; 115: 2848-2855.
22. Spargias K, Alexopoulos E, Thomopoulou S, et al,. Effect of balloon valvuloplasty in patients with severe aortic stenosis on levels of N-terminal pro-B-type natriuretic peptide. Am J Cardiol 2009; 104: 846-849.